General MedicationsOPHTHALMICGeneric
VIRA-A
VIDARABINE
Standard Dose
3%
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Discontinued
Summary
Approval overview VIRA-A is listed in Drugs@FDA under application 050486 (NDA).
Review priority: PRIORITY Marketing status: Discontinued Active ingredient VIDARABINE Form and strength OINTMENT;OPHTHALMIC - 3% Sponsor PARKEDALE Submission history Latest submission status date: 1999-07-26 00:00:00.
Structured Monograph
Clinical summary
Approval overview VIRA-A is listed in Drugs@FDA under application 050486 (NDA). Review priority: PRIORITY Marketing status: Discontinued Active ingredient VIDARABINE Form and strength OINTMENT;OPHTHALMIC - 3% Sponsor PARKEDALE Submission history Latest submission status date: 1999-07-26 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.